Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

Experimental Neurology

Volumn 273, Issue , 2015, Pages 36-44

  Mounsey, Ross B ^a   Mustafa, Sarah ^a   Robinson, Lianne ^a,b   Ross, Ruth A ^c   Riedel, Gernot ^a   Pertwee, Roger G ^a   Teismann, Peter ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Endocannabinoids; MPTP; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 ARACHIDONOYLGLYCEROL; CYCLOOXYGENASE 2 INHIBITOR; DFU; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 2-ARACHIDONYLGLYCEROL; 4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; 5,5-DIMETHYL-3-(3-FLUOROPHENYL)-4-(4-METHYLSULFONYL)PHENYL-2(5H)-FURANONE; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; CYCLOOXYGENASE 2; ENDOCANNABINOID; ENZYME INHIBITOR; FURAN DERIVATIVE; NEUROPROTECTIVE AGENT; NEUROTOXIN; PIPERIDINE DERIVATIVE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG POTENTIATION; ENZYMATIC DEGRADATION; ENZYME INHIBITION; IMMUNE RESPONSE; INFLAMMATION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BRAIN; C57BL MOUSE; COMPLICATION; DIET THERAPY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GAIT DISORDERS, NEUROLOGIC; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; TIME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ARACHIDONIC ACIDS; BENZODIOXOLES; BRAIN; CELL DEATH; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; ENZYME INHIBITORS; FURANS; GAIT DISORDERS, NEUROLOGIC; GLYCERIDES; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PARKINSON DISEASE; PIPERIDINES; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84939154942     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.07.024     Document Type: Article

References (60)

1. Atwood B.K., Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 2010, 160:467-479.
2. Aymerich M.S., Rojo-Bustamante E., Molina C., Celorrio M., Sanchez-Arias J.A., Franco R. Neuroprotective effect of JZL184 in MPP-treated SH-SY5Y cells through CB receptors. Mol. Neurobiol. 2015, 10.1007/s12035-015-9213-3.
3. Bilsland L.G., Dick J.R., Pryce G., Petrosino S., Di Marzo V., Baker D., Greensmith L. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 2006, 20:1003-1005.
4. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernandez-Ruiz J.J., Di Marzo V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 1999, 256:377-380.
5. Blankman J.L., Simon G.M., Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 2007, 14:1347-1356.
6. Blazquez C., Chiarlone A., Sagredo O., Aguado T., Pazos M.R., Resel E., Palazuelos J., Julien B., Salazar M., Borner C., Benito C., Carrasco C., Diez-Zaera M., Paoletti P., Diaz-Hernandez M., Ruiz C., Sendtner M., Lucas J.J., de Yebenes J.G., Marsicano G., Monory K., Lutz B., Romero J., Alberch J., Gines S., Kraus J., Fernandez-Ruiz J., Galve-Roperh I., Guzman M. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2011, 134:119-136.
7. Blazquez C., Chiarlone A., Bellocchio L., Resel E., Pruunsild P., Garcia-Rincon D., Sendtner M., Timmusk T., Lutz B., Galve-Roperh I., Guzman M. The CB cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death Differ. 2015, 10.1038/cdd.2015.11.
8. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 1995, 202:17-20.
9. Chen X., Zhang J., Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons against beta-amyloid insults. Neuroscience 2011, 178:159-168.
10. Chiarlone A., Bellocchio L., Blazquez C., Resel E., Soria-Gomez E., Cannich A., Ferrero J.J., Sagredo O., Benito C., Romero J., Sanchez-Prieto J., Lutz B., Fernandez-Ruiz J., Galve-Roperh I., Guzman M. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:8257-8262.
11. Comelli F., Giagnoni G., Bettoni I., Colleoni M., Costa B. The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br. J. Pharmacol. 2007, 152:787-794.
12. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2004, 39:889-909.
13. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535.
14. Dehmer T., Lindenau J., Haid S., Dichgans J., Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 2000, 74:2213-2216.
15. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10819-10824.
16. Dowie M.J., Howard M.L., Nicholson L.F., Faull R.L., Hannan A.J., Glass M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience 2010, 170:324-336.
17. Du H., Chen X., Zhang J., Chen C. Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-gamma. Br. J. Pharmacol. 2011, 163:1533-1549.
18. Fernandez-Suarez D., Celorrio M., Riezu-Boj J.I., Ugarte A., Pacheco R., Gonzalez H., Oyarzabal J., Hillard C.J., Franco R., Aymerich M.S. The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. Neurobiol. Aging 2014, 35:2603-2616.
19. Fontanellas A., Manzanares J., Garcia-Bravo M., Buzaleh A.M., Mendez M., Oliva J.M., Batlle A., Palomo T., Enriquez de Salamanca R. Effects of repeated administration with CP-55,940, a cannabinoid CB1 receptor agonist on the metabolism of the hepatic heme. Int. J. Biochem. Cell Biol. 2005, 37:1620-1625.
20. Garcia C., Palomo C., Garcia-Arencibia M., Ramos J.A., Pertwee R.G., Fernandez-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid D(9)-THCV in animal models of Parkinson's disease. Br. J. Pharmacol. 2011, 163:1495-1506.
21. Gundersen H.J., Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 1987, 147:229-263.
22. Hohmann A.G., Suplita R.L., Bolton N.M., Neely M.H., Fegley D., Mangieri R., Krey J.F., Walker J.M., Holmes P.V., Crystal J.D., Duranti A., Tontini A., Mor M., Tarzia G., Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005, 435:1108-1112.
23. Iuvone T., Esposito G., De Filippis D., Bisogno T., Petrosino S., Scuderi C., Di Marzo V., Steardo L., Endocannabinoid Research Group Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. J. Mol. Med. 2007, 85:1379-1392.
24. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2007, 2:141-151.
25. Kelsey J.E., Harris O., Cassin J. The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behav. Brain Res. 2009, 203:304-307.
26. King A.R., Duranti A., Tontini A., Rivara S., Rosengarth A., Clapper J.R., Astarita G., Geaga J.A., Luecke H., Mor M., Tarzia G., Piomelli D. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem. Biol. 2007, 14:1357-1365.
27. Kozak K.R., Rowlinson S.W., Marnett L.J. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J. Biol. Chem. 2000, 275:33744-33749.
28. Kreutz S., Koch M., Bottger C., Ghadban C., Korf H.W., Dehghani F. 2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells. Glia 2009, 57:286-294.
29. Lastres-Becker I., de Miguel R., De Petrocellis L., Makriyannis A., Di Marzo V., Fernandez-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J. Neurochem. 2003, 84:1097-1109.
30. Lastres-Becker I., Molina-Holgado F., Ramos J.A., Mechoulam R., Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 2005, 19:96-107.
31. Liberatore G., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.J., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat. Med. 1999, 5:1403-1409.
32. Long J.Z., Nomura D.K., Vann R.E., Walentiny D.M., Booker L., Jin X., Burston J.J., Sim-Selley L.J., Lichtman A.H., Wiley J.L., Cravatt B.F. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20270-20275.
33. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavon F.J., Serrano A.M., Selley D.E., Parsons L.H., Lichtman A.H., Cravatt B.F. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 2009, 5:37-44.
34. Long J.Z., Jin X., Adibekian A., Li W., Cravatt B.F. Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases. J. Med. Chem. 2010, 53:1830-1842.
35. Mackie K., Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 2006, 8:E298-E306.
36. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
37. Melis M., Pillolla G., Bisogno T., Minassi A., Petrosino S., Perra S., Muntoni A.L., Lutz B., Gessa G.L., Marsicano G., Di Marzo V., Pistis M. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol. Dis. 2006, 24:15-27.
38. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 1994, 165:208-210.
39. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 1994, 180:147-150.
40. Mukhopadhyay P., Pan H., Rajesh M., Batkai S., Patel V., Harvey-White J., Mukhopadhyay B., Hasko G., Gao B., Mackie K., Pacher P. CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Br. J. Pharmacol. 2010, 160:657-668.
41. Muller T., Blum-Degen D., Przuntek H., Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol. Scand. 1998, 98:142-144.
42. Nomura D.K., Morrison B.E., Blankman J.L., Long J.Z., Kinsey S.G., Marcondes M.C., Ward A.M., Hahn Y.K., Lichtman A.H., Conti B., Cravatt B.F. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334:809-813.
43. Palazuelos J., Aguado T., Pazos M.R., Julien B., Carrasco C., Resel E., Sagredo O., Benito C., Romero J., Azcoitia I., Fernandez-Ruiz J., Guzman M., Galve-Roperh I. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009, 132:3152-3164.
44. Pan B., Wang W., Long J.Z., Sun D., Hillard C.J., Cravatt B.F., Liu Q.S. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) enhances retrograde endocannabinoid signaling. J. Pharmacol. Exp. Ther. 2009, 331:591-597.
45. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001, 413:527-531.
46. Panikashvili D., Mechoulam R., Beni S.M., Alexandrovich A., Shohami E. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J. Cereb. Blood Flow Metab. 2005, 25:477-484.
47. Price D.A., Martinez A.A., Seillier A., Koek W., Acosta Y., Fernandez E., Strong R., Lutz B., Marsicano G., Roberts J.L., Giuffrida A. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur. J. Neurosci. 2009, 29:2177-2186.
48. Ramirez B.G., Blazquez C., Gomez del Pulgar T., Guzman M., de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 2005, 25:1904-1913.
49. Riendeau D., Percival M.D., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Falgueyret J.P., Ford-Hutchinson A.W., Gordon R., Greig G., Gresser M., Guay J., Kargman S., Leger S., Mancini J.A., O'Neill G., Ouellet M., Rodger I.W., Therien M., Wang Z., Webb J.K., Wong E., Chan C.C. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br. J. Pharmacol. 1997, 121:105-117.
50. Sagredo O., Garcia-Arencibia M., de Lago E., Finetti S., Decio A., Fernandez-Ruiz J. Cannabinoids and neuroprotection in basal ganglia disorders. Mol. Neurobiol. 2007, 36:82-91.
51. Sathe K., Maetzler W., Lang J.D., Mounsey R.B., Fleckenstein C., Martin H.L., Schulte C., Mustafa S., Synofzik M., Vukovic Z., Itohara S., Berg D., Teismann P. S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain 2012, 135:3336-3347.
52. Schlosburg J.E., Blankman J.L., Long J.Z., Nomura D.K., Pan B., Kinsey S.G., Nguyen P.T., Ramesh D., Booker L., Burston J.J., Thomas E.A., Selley D.E., Sim-Selley L.J., Liu Q.S., Lichtman A.H., Cravatt B.F. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci. 2010, 13:1113-1119.
53. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:5473-5478.
54. Tieu K., Perier C., Vila M., Caspersen C., Zhang H.P., Teismann P., Jackson-Lewis V., Stern D.M., Yan S.D., Przedborski S. l-3-Hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's disease. Ann. Neurol. 2004, 56:51-60.
55. Valdeolivas S., Pazos M.R., Bisogno T., Piscitelli F., Iannotti F.A., Allara M., Sagredo O., Di Marzo V., Fernandez-Ruiz J. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. Cell. Death Dis. 2013, 4:e862.
56. van der Stelt M., Mazzola C., Esposito G., Matias I., Petrosino S., De Filippis D., Micale V., Steardo L., Drago F., Iuvone T., Di Marzo V. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci. 2006, 63:1410-1424.
57. Vandevoorde S., Jonsson K.O., Labar G., Persson E., Lambert D.M., Fowler C.J. Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br. J. Pharmacol. 2007, 150:186-191.
58. West M.J. New stereological methods for counting neurons. Neurobiol. Aging 1993, 14:275-285.
59. Zhang J., Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J. Biol. Chem. 2008, 283:22601-22611.
60. Zhang J., Hu M., Teng Z., Tang Y.P., Chen C. Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease. J. Neurosci. 2014, 34:14919-14933.